secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173803
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Seres stockholders approve increase in authorized shares from 200M to 240M at annual meeting
--------------------------------------------------------------------------------

- All three Class II director nominees elected: Berenson, Kender, and Fraser.
- Amendment to increase authorized common shares to 240M approved with 98.4% of votes cast in favor.
- Ratification of PwC as auditor for FY2023 approved with 99.8% of votes cast in favor.
- Advisory vote on executive compensation passed with approximately 99.4% of votes cast in favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523173803/0001193125-23-173803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523173803/d518244d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer